Ketogenic Diet Enhances CAR T Cell Therapy

Researchers from the University of Pennsylvania have discovered that a ketogenic diet can significantly enhance the effectiveness of CAR T cell therapy in treating lymphoma, as evidenced by improved tumor control and survival rates in mouse models. The study, presented at the American Society of Hematology Annual Meeting, highlights beta-hydroxybutyrate (BHB), a metabolite produced during ketosis, as a preferred energy source for CAR T cells, which enhances their cancer-fighting capabilities. Preliminary findings suggest that BHB supplementation could provide a low-toxicity, cost-effective method to improve patient outcomes in CAR T cell treatment. This innovative approach shifts focus from genetic modifications to dietary interventions, potentially expanding the efficacy of CAR T therapies that have seen high relapse rates. A Phase I clinical trial is underway to further assess the impact of BHB on CAR T cell function in lymphoma patients. If successful, this strategy could represent a significant advancement in cancer immunotherapy.